• Market Authorisation received for Liquid Paracetamol plus Caffeine Soft Gel
• Builds on 3 other MAs for Liquid Paracetamol, Liquid Paracetamol plus Ibuprofen, and Liquid Mini-Ibuprofen
• Validation of Company's innovation and capabilities

Wellnex Life Limited (ASX:WNX) has announced that it has received a new Market Authorisation (MA) from the Therapeutic Goods Administration (TGA) for its Liquid Paracetamol plus Caffeine Soft Gel product. This new MA adds to the Company's existing portfolio of 3 other MAs, including Liquid Paracetamol, Liquid Paracetamol plus Ibuprofen, and Liquid Mini-Ibuprofen. The approval of this new MA is a validation of Wellnex Life's philosophy of being either 'first' or 'fast' to market with innovative products for the consumer health market. The new MA will provide further revenue opportunities for the Company, as it can be used in Wellnex Life's own brands as well as licensed to third parties, including domestic and international companies like Chemist Warehouse and Haleon. The Managing Director, Zack Bozinovski, stated that the approval of the liquid paracetamol plus caffeine soft gel MA is a great testament to the Company's internal capabilities and will provide opportunities to use the product in the Company's own brands as well as license it to third parties.